Take on Typhoid core slides

Slides:



Advertisements
Similar presentations
R&D Financing by the Bill & Melinda Gates Foundation
Advertisements

Module 1 Introduction to rotavirus disease and vaccine
Global Measles and Rubella Strategic Plan
Critical conversations in Public-private partnerships Dr Ranjana Kumar 1 st November 2007.
Pertussis Disease Pertussis (‘whooping cough’) is a bacterial infection affecting the respiratory system, caused by the organism Bordetella pertussis.
More proven interventions are available to prevent and treat diarrhea than any other major child killer Jones G Bryce J. et al. Lancet UNICEF. Diarrhoea:
Update on Vaccines not Included in this Tender: Rotavirus Vaccines Pre Tender Meeting UNICEF Supply Division, 10-11th December 2008 Ann Ottosen.
Working Together to Improve Global Health
Hepatitis B and Hepatitis B Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
TYPHOID FEVER By: Jenae Barsh. DESCRIPTION  Typhoid Fever is life-threatening illness caused by the bacterium Salmonella Typhi.  It is commonly found.
A global partnership to stop measles & rubella The Measles & Rubella Initiative: Preparing for the Next Decade Lisa Cairns, MD, MPH Sept 18, 2012 Washington,
George A. Ralls M.D. Dave Freeman Health Services Department September 1st, 2009 INFLUENZA UPDATE.
Pandemic Influenza Preparedness Kentucky Department for Public Health Department for Public Health.
The partners,initiatives, alliances, groups and meetings within world of the Expanded Programme on Immunization Quick overview 25-September-2012 GID presentation.
20 Answers About Influenza
Departmental Perspectives on Viral Hepatitis
Biological Hazards Disease in Developed and Developing Countries.
Prevention and Control of Viral Hepatitis Infection: WHO Framework for Global Action Prevention and Control of Viral Hepatitis Infection: WHO Framework.
Infrastructure Consortium Meeting June IFF for Immunziation Andrew Jones Senior Programme Officer, Innovative Financing.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Safe Immunization Practices and Prevention of Hepatitis B and C Susan Mackay Behaviour Change Project Safe Injection Global Network.
Polio Eradication  Although the number of endemic countries is at an all-time low in 2002, the actual number of cases was approximately four times higher.
A Potential Influenza Pandemic: Possible Macroeconomic Effects and Policy Issues Julie Somers Congressional Budget Office Prepared for the Ninth Annual.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Establishing a Global Vaccine Development Fund Peter Hale The Foundation for Vaccine Research Washington, DC Consultation on Financing of R&D Preparedness.
The Vermont Department of Health Update on Pandemic Threat Cort Lohff, MD, MPH State Epidemiologist Guidance Support Prevention Protection.
Public Health and Disease Notes. Terms Relating to Disease Public health – the patient is the population Epidemiology - the study of the incidence, distribution.
Notes: Spread, Treatment, and Prevention of Disease
1 Module 1: [Basic] Unit 1: [HIV Epidemics and Key Populations] Lesson 2: [Levels of HIV Epidemic in the World] “Community-Based HIV Surveillance” Online.
Health Risks in India: Cholera
South Dakota Department of Health
Response to the Yellow Fever Outbreak in the WHO African Region: What has been done? Dr Ambrose Talisuna, WHO-Regional Office for Africa-AFRO Brazzaville-Congo.
Seasonal Malaria Chemoprevention: WHO Policy and Perspectives
We know what to do: the unfinished agenda and priority next steps
ROTAVIRUS COMMON, SEVERE, DEVASTATING, PREVENTABLE
Ebola, Avian Flu & HIV/AIDS
WASH and Cholera Preparedness to Response-
WHO AFRO Technical Coordinator for Health Emergencies
How does teamwork improve value. Dr Nils E
More proven interventions are available to prevent and treat diarrhea than any other major child killer Jones G Bryce J. et al. Lancet Investing.
Polio Eradication: Global Update 17June 2014
Water: Human right or commodity?
Spread, Treatment, and Prevention of Disease
POLIOPLUS FACT SHEET Feb 2018
Progress and Challenges with achieving Universal Immunization Coverage
Module 8 Safety and acceptability of multiple injections
Safety and acceptability of multiple injections
Life Expectancy and Child Mortality
Dengue Prevention in Asia
Water: Human right or commodity?
Think Locally, Act Globally
World Vision’s WASH Program
JE vaccine eligibility
Module 8 Safety and acceptability of multiple injections
Module 1 Introduction to rotavirus disease and vaccine
Module 1 Introduction to rotavirus disease and vaccine
Module 1 Introduction to rotavirus disease and vaccine
Provincial Measles Immunization Catch-Up Program
Module 1 Introduction to rotavirus disease and vaccine
Module 1 Introduction to rotavirus disease and vaccine
State of Measles Initiative Financing Partners for Measles Advocacy Meeting Washington, D.C. September 22, 2008 Andrea Gay.
Financing Malaria: The Global Fund perspective
Maintaining Elimination in an Environment of Persistent Importation
Clean Water Malaria HIV/AIDS
YELLOW FEVER VACCINE AVAILABILITY AND NEEDS FOR THE AFRICAN REGION

Polio Eradication Progress & Challenges.
Chief, Meningitis and Vaccine Preventable Diseases Branch
Developing a Financial Sustainability Plan for Cambodia
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

Take on Typhoid core slides NAME TITLE DATE (Optional) PATH/Rocky Prajapati

Typhoid burden Typhoid continues to be a substantial public health threat that disproportionately impacts children and marginalized populations in much of Asia and sub-Saharan Africa. The burden of typhoid is likely underestimated due to challenges in surveillance and available diagnostics. Current estimate is nearly 12 million cases and more than 128,000 deaths each year. Vaccination, along with improvements in water, sanitation, and hygiene (WASH), are key components to an integrated strategy to prevent typhoid. PATH/Doune Porter.

Why TCVs? Until recently, the two typhoid vaccines that were available were underutilized in high-burden countries despite typhoid’s substantial and detrimental impact and World Health Organization (WHO) recommendation for their use. New typhoid conjugate vaccines (TCVs) have the potential to overcome many challenges that have impeded the uptake of earlier vaccines through: Longer-lasting protection; Suitability for children under the age of two, and; Easier inclusion in routine immunization programs. PATH/Rocky Prajapati.

Building momentum around recent developments In the past few months, several milestones for global TCV policies have been reached: October 2017: WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization recommended introduction of TCVs in typhoid-endemic countries. November 2017: Gavi, the Vaccine Alliance announced US$85 million in funding to support TCV introduction in Gavi-eligible countries. December 2017: WHO prequalified the first TCV, Typbar- TCV®. March 2018: New WHO position paper recommending routine introduction of TCVs in typhoid-endemic countries. April 2018: Gavi application available for countries to apply for support to introduce TCV. Bill & Melinda Gates Foundation/Sam Reinders.

Typbar-TCV® Typbar-TCV, manufactured by Bharat Biotech, is the first typhoid conjugate vaccine to be prequalified by WHO. It is approved as a single dose for adults, children, and infants 6 months of age and older. First typhoid vaccine to be approved for children younger than 2 years. Offers protection for at least 3 years. Additional studies are needed to determine the duration of protection and need for booster doses. Studies have shown that Typbar-TCV elicits a strong immune response in infants and adults. Bill & Melinda Gates Foundation/Sam Reinders.

Now is the time to take on typhoid We currently face a triple threat that elevates the urgency for better prevention and control of typhoid: Urbanization: Rapid urbanization is leading to overcrowded populations in cities across Asia and sub-Saharan Africa that often have outdated, inadequate, or unsafe sanitation systems, increasing the risk of typhoid transmission. Climate change: Higher likelihood for natural disasters to occur. During droughts, shallow water sources are more likely to be contaminated with typhoid; flooding can overwhelm sewage systems or sanitation facilities, allowing human waste to contaminate water sources. Drug resistance: Drug- and multidrug-resistant strains of typhoid are spreading and becoming more difficult to treat. PATH/Monique Berlier.

Drug-resistant typhoid is increasing Recent outbreaks show an alarming trend of drug- and multidrug-resistant typhoid strains. Numerous recent outbreaks in Africa have included multidrug-resistant strains. An ongoing outbreak in Pakistan is the first outbreak of ceftriaxone-resistant typhoid. There are no treatment guidelines for ceftriaxone- resistant typhoid. New research shows that the strain in Pakistan (H58) is extensively drug resistant and can easily spread in a variety of diverse geographic settings. Resistant strains have been reported for each class of antibiotics used to treat typhoid. We are running out of effective options to treat drug-resistant typhoid, raising the urgency for preventive measures like typhoid conjugate vaccines and improved WASH. Global prevalence of H58 typhoid strains, 2015 Wellcome Sanger Institute.

Learn more at: http://takeontyphoid.org PATH/Rocky Prajapati

Take on Typhoid partnership In September 2017, TyVAC and the Coalition against Typhoid joined forces to launch the Take On Typhoid partnership. Building on the momentum, experience, and expertise of diverse partners, Take On Typhoid focuses attention on typhoid and the need for typhoid conjugate vaccines and water, sanitation, and hygiene to reduce the burden and impact of typhoid fever. Visit the www.takeontyphoid.org website for advocacy resources, blogs, publications, and more. PATH/Georgina Goodwin.